Recent studies have converged on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic signaling. While GIP stimulators are commonly employed for treating type 2 diabetes mellitus, their potential impacts on reinforcement circuits, specifically influenced by dopa